A Clinical Guide to Suitability, Risks, and Long-Term Knee Pain Relief

Margaret had lived with knee pain for nearly four years. She had tried physiotherapy, cortisone injections, and anti-inflammatory tablets. Nothing gave her lasting relief. Her GP referred her to an orthopedic consultant, who mentioned a newer treatment she had never heard of: an Arthrosamid injection. She searched online, typed “arthrosamid injection cost UK” into her browser, and found herself down a rabbit hole of clinical studies, private clinic pages, and patient forums. She wanted facts. She wanted to know whether this treatment was actually right for her — or whether she was simply hoping for a solution that did not apply to her situation.

What Is an Arthrosamid Injection?

developed as an alternative to repeat injections and, in carefully selected patients, as a way of delaying or avoiding knee replacement surgery. A single Arthrosamid injection can provide pain relief for up to two years or more, according to published clinical data.

It received CE marking in Europe and has been available in the United Kingdom through licensed private clinics. The NHS does not currently fund Arthrosamid as a standard treatment, though clinical interest continues to grow as evidence accumulates.

How Does It Work?

When the hydrogel is injected into the knee joint, it integrates with the synovial membrane — the soft tissue lining of the joint. It does not simply sit in the joint fluid and wash away. Instead, it anchors into the tissue and provides a permanent cushioning effect, reducing the mechanical stress on the joint surface.

This mechanism is distinct from steroid injections, which reduce inflammation temporarily, and from hyaluronic acid injections, which supplement the joint fluid. Arthrosamid works at a structural level, which is why its effects tend to last considerably longer.

Who Is a Suitable Candidate for Arthrosamid?

Not everyone with knee pain is appropriate for this treatment. Arthrosamid is not a universal solution. The treatment works best in a specific patient profile. Understanding this profile is essential before pursuing the procedure.

Patients with Mild to Moderate Osteoarthritis

Arthrosamid is clinically indicated for patients with mild to moderate knee osteoarthritis (OA). The published research, including the HYDRA trial — one of the most cited studies on this treatment — focused on patients with Grade 1 to Grade 3 osteoarthritis on the Kellgren-Lawrence scale.

Patients with Grade 1 or Grade 2 OA typically show the strongest response. The joint still has enough structural integrity to benefit from the cushioning effect of the hydrogel. In Grade 3 cases, benefit is still possible, but patient selection becomes more nuanced.

Patients Who Have Not Responded to Conservative Treatments

Arthrosamid is generally considered after other treatments have failed to provide sufficient relief. If physiotherapy, weight management, oral analgesia, and corticosteroid or hyaluronic acid injections have not worked, Arthrosamid becomes a clinically reasonable next step.

NICE (the National Institute for Health and Care Excellence) guidance on osteoarthritis emphasises a stepped approach to care, beginning with lifestyle modifications and progressing through pharmacological and procedural options. Arthrosamid sits within this progressive framework, typically considered before surgical intervention.

Patients Who Are Not Yet Ready for, or Suitable for, Knee Replacement

Not every patient with knee pain is ready for surgery. Some are too young, some have medical comorbidities that increase surgical risk, and others simply wish to delay surgery for personal or professional reasons. Arthrosamid can act as a bridge — providing meaningful relief while preserving the option of surgery later.

For patients in their 40s, 50s, or even early 60s with significant osteoarthritis, an Arthrosamid injection in London or other UK centres can offer a window of improved function without the recovery demands of joint replacement.

Patients with a BMI Below 35

Clinical evidence supports better outcomes in patients with a body mass index (BMI) under 35. Higher BMI places greater mechanical load on the joint, which may limit the degree of benefit. This is not an absolute exclusion in all clinical protocols, but it is a relevant factor that a trained clinician will consider.

Patients Seeking a Long-Term, Non-Surgical Option

Some patients simply do not want surgery. For these individuals, Arthrosamid offers a clinically supported alternative that is minimally invasive, performed as an outpatient procedure, and carries a low complication profile. The procedure takes around 30 to 45 minutes, requires no general anaesthetic, and involves a relatively short recovery period.

Understanding Arthrosamid Injection Cost in the UK

Arthrosamid injection cost in the UK varies between clinics, and it is important to understand what drives this variation. As of current pricing at leading private clinics, the arthrosamid injection cost typically start from £2800 per knee, depending on location, the clinic’s overhead, the experience of the administering clinician, and what the fee includes.

Arthrosamid injection cost in London tends to sit at the higher end of the range, reflecting the costs associated with Harley Street and other central London clinical environments. This does not mean patients outside London should travel for the cheapest option. The experience and credentials of the clinician matter far more than the headline price.

When researching “arthrosamid injection near me” or “arthrosamid injections near me,” patients should look for:

• A clinician with specific training in musculoskeletal or aesthetic medicine
• A clinic that performs pre-procedure imaging (typically ultrasound or X-ray) to confirm joint suitability
• Transparent pricing with a clear breakdown of what is included
• Access to follow-up care and post-procedure support

The arthrosamid injection cost should always be viewed in the context of the full clinical package — not simply the procedure fee in isolation.

Who Is NOT a Suitable Candidate for Arthrosamid?

This section is just as important as the one above. Understanding who should not have this treatment protects patients from unnecessary procedures, wasted expenditure, and potential harm.

Patients with Severe (Grade 4) Osteoarthritis

In Grade 4 osteoarthritis, the joint cartilage is extensively or completely worn away. Bone-on-bone contact limits the effectiveness of a hydrogel implant. The structural environment no longer supports the mechanism by which Arthrosamid works. In these cases, the clinical consensus typically points toward knee replacement as the appropriate intervention.

Patients with Active Joint Infection or Inflammatory Arthritis

Arthrosamid is contraindicated in patients with an active infection in or around the knee joint. Injecting into an infected joint carries serious risk of septic arthritis. Similarly, patients with inflammatory arthritis conditions — such as rheumatoid arthritis or psoriatic arthritis — require different management strategies. These conditions involve an autoimmune component that Arthrosamid does not address.

Patients with Known Allergy to Polyacrylamide

Although rare, some individuals may have a sensitivity to polyacrylamide. A thorough allergy history must be taken before the procedure. If there is any concern, the procedure should not proceed.

Patients Who Have Recently Had a Corticosteroid Injection

Timing matters. Most clinical protocols recommend waiting at least six to twelve weeks after a corticosteroid injection before proceeding with Arthrosamid. Steroids can affect the local tissue environment and may influence how the hydrogel integrates with the synovial membrane.

Patients with Significant Knee Instability or Ligamentous Damage

If the knee joint is mechanically unstable due to ligament damage — for example, an untreated ACL or PCL injury — Arthrosamid is unlikely to provide sufficient benefit. Structural instability is a different problem to cartilage loss, and it requires a different solution. A clinician will assess this through examination and imaging before recommending any intra-articular treatment.

Patients Expecting Complete Pain Elimination

Arthrosamid is not a cure. It is a pain management tool with a strong evidence base, but it does not regenerate cartilage, reverse structural changes, or guarantee complete freedom from discomfort. Patients who arrive with unrealistic expectations are poor candidates — not because of their anatomy, but because of misaligned goals.

A good clinician will have an honest conversation about what the treatment can and cannot achieve before proceeding.

The Importance of a Clinical Assessment

No article, however well-researched, replaces a consultation. The criteria above are guides, not verdicts. Individual anatomy, health history, imaging findings, symptom patterns, and personal goals all influence whether Arthrosamid is the right choice for a specific patient.

Dr Syed Nadeem Abbas, who leads the team at DSNA Clinic on Harley Street, takes a rigorous, evidence-based approach to patient selection for intra-articular treatments. This kind of careful assessment protects patients and ensures that those who proceed with the treatment are genuinely likely to benefit.

A good consultation will include a review of your imaging, a physical assessment of the joint, and a frank discussion about your expectations. If a clinic offers Arthrosamid without any of these elements, that is a warning sign worth taking seriously.

What the Evidence Says

The HYDRA trial, published in peer-reviewed literature, demonstrated statistically significant improvements in pain, stiffness, and physical function in patients treated with Arthrosamid compared to baseline. These improvements were sustained at the 12-month and 24-month follow-up points.

The treatment has also been reviewed in the context of real-world clinical use across European centres. Long-term safety data are reassuring, with no systemic adverse effects reported in published series and a low rate of local complications.

NICE and the British Medical Journal have both noted the growing evidence base for polyacrylamide hydrogel in osteoarthritis management, while acknowledging that further large-scale randomised controlled trials would strengthen the evidence further. The treatment is not yet commissioned by the NHS, but it is regulated, CE-marked, and available through licensed private practitioners.

After the Procedure: What to Expect

Improvement in pain and function generally develops progressively over six to twelve weeks. Some patients notice meaningful change earlier. Regular review allows the clinician to monitor progress and address any concerns.

Physical activity guidance varies by individual, but most patients are advised to avoid high-impact exercise for a short period post-procedure and to gradually return to activity as symptoms permit.

A Clear-Eyed Summary

Arthrosamid is a well-supported, minimally invasive treatment for mild to moderate knee osteoarthritis in patients who have not responded adequately to conservative measures and who are not yet at the point of requiring joint replacement. It is not appropriate for severe osteoarthritis, active infection, inflammatory joint disease, or patients with unrealistic expectations.

The arthrosamid injection cost in the UK reflects a premium, private procedure — and patients should research both the price and the credentials behind it. Searching for “arthrosamid injection near me” is a reasonable starting point, but the quality of the clinical assessment is what ultimately determines whether the procedure is worthwhile.

The treatment will not be right for everyone who wants it. But for the right patient, it offers a meaningful, evidence-based path to sustained pain relief — without surgery, without repeated injections, and without the recovery demands of a major orthopaedic procedure.

Read More:

Arthrosamid or Surgery? When Injection Is the Better Option for Knee Osteoarthritis

What to Expect During an Arthrosamid Injection Procedure: Step by Step